Soleno Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Soleno Therapeutics is gedaald met een gemiddeld jaarlijks tempo van -24.2%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19%.

Belangrijke informatie

-24.2%

Groei van de winst

34.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-49.6%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Nov 08

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 10

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Dec 07

Opbrengsten en kosten

Hoe Soleno Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:SLNO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	0	-131	73	66
30 Jun 24	0	-65	27	42
31 Mar 24	0	-52	19	34
31 Dec 23	0	-39	13	25
30 Sep 23	0	-33	12	20
30 Jun 23	0	-28	11	18
31 Mar 23	0	-27	10	17
31 Dec 22	0	-24	10	15
30 Sep 22	0	-21	10	15
30 Jun 22	0	-23	10	16
31 Mar 22	0	-28	10	18
31 Dec 21	0	-31	11	21
30 Sep 21	0	-31	10	23
30 Jun 21	0	-31	10	23
31 Mar 21	0	-28	10	24
31 Dec 20	0	-25	9	23
30 Sep 20	0	-36	8	23
30 Jun 20	0	-27	7	23
31 Mar 20	0	-30	7	20
31 Dec 19	0	-31	7	16
30 Sep 19	0	-16	7	13
30 Jun 19	0	-19	7	11
31 Mar 19	0	-16	7	9
31 Dec 18	0	-12	7	7
30 Sep 18	0	-16	7	6
30 Jun 18	0	-17	7	5
31 Mar 18	0	-13	7	4
31 Dec 17	0	-12	7	3
30 Sep 17	0	-13	6	2
30 Jun 17	0	-11	6	2
31 Mar 17	0	-9	4	1
31 Dec 16	0	-10	6	2
30 Sep 16	0	-8	7	3
30 Jun 16	0	-10	8	4
31 Mar 16	1	-7	9	5
31 Dec 15	0	-10	6	0
30 Sep 15	0	-20	7	4
30 Jun 15	0	-19	5	4
31 Mar 15	0	-24	4	3
31 Dec 14	0	-13	3	2
30 Sep 14	0	-7	2	2
30 Jun 14	0	-6	2	2
31 Mar 14	0	-6	1	2
31 Dec 13	3	-4	1	2

Kwaliteitswinsten: SLNO is momenteel verliesgevend.

Groeiende winstmarge: SLNO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SLNO is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 24.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SLNO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SLNO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 13.6% ).

Rendement op eigen vermogen

Hoge ROE: SLNO heeft een negatief Return on Equity ( -49.55% ), omdat het momenteel verliesgevend is.

Soleno Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Forecast to breakeven in 2026

Price target increased by 8.0% to US$73.57

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

President recently sold US$1.1m worth of stock

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold US$800k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Independent Chairman exercised options to buy US$2.6m worth of stock.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold US$785k worth of stock

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Price target lowered to US$7.00

New 90-day low: US$1.38

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: US$2.74

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Soleno Therapeutics: Could Be Big Fish In The Small Pond

New 90-day high: US$2.10

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation